A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-29. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
suborder Clypeasterina family Clypeasteridae L. Agassiz, 1835 family Fossulasteridae Philip & Foster, 1971 † family Scutellinoididae Irwin, 1995 † family Conoclypeidae von Zittel, 1879 † family Faujasiidae Lambert, 1905 † family Oligopygidae Duncan, 1889 † family Plesiolampadidae Lambert, 1905 † suborder Scutellina infraorder Laganiformes family Echinocyamidae Lambert & Thiéry, 1914 family Fibulariidae Gray, 1855 family Laganidae Desor, 1858 infraorder Scutelliformes family Echinarachniidae Lambert in Lambert & Thiéry, 1914 family Eoscutellidae Durham, 1955 † family Protoscutellidae Durham, 1955 † family Rotulidae Gray, 1855 superfamily Scutelloidea Gray, 1825 family Abertellidae Durham, 1955 † family Astriclypeidae Stefanini, 1912 family Dendrasteridae Lambert, 1900 -- Pacific eccentric sand dollar. family Mellitidae Stefanini, 1912 -- Keyhole sand dollars family Monophorasteridae Lahille, 1896 † family Scutasteridae Durham, 1955 † family Scutellidae Gray, 1825 family Taiwanasteridae Wang, 1984 family Scutellinidae Pomel, 1888a † However, the traditional Clypeasteroida is currently not thought to represent a monophyletic group because the Clypeasterina and Scutellina are most likely not each other's closest relatives. Their similarities are possibly the result of convergent evolution. They are part of clade Luminacea, which also includes the orders Cassiduloida and Echinolampadoida. In a recent classification, Clypeasteroida includes only the former Clypeasterina.
The raised white blood cell count and creatine phosphokinase (CPK) plasma concentration seen in those with NMS is due to increased muscular activity and rhabdomyolysis (destruction of muscle tissue). Someone may experience hypertensive crisis and metabolic acidosis. The fever seen with NMS is believed to be caused by hypothalamic dopamine receptor blockade. Antipsychotics cause an increased calcium release from the sarcoplasmic reticulum of muscle cells which can result in rigidity and eventual cell breakdown. No major studies have reported an explanation for the abnormal EEG, but it is likely also attributable to dopamine blockage leading to changes in neuronal pathways.
Like the Aztecs, the Pueblo, Navajo and Apache tribes cherished turquoise for its amuletic use; the latter tribe believe the stone to afford the archer dead aim. In Navajo culture it is used for "a spiritual protection and blessing." Among these peoples turquoise was used in mosaic inlay, in sculptural works, and was fashioned into toroidal beads and freeform pendants. The Ancestral Puebloans (Anasazi) of the Chaco Canyon and surrounding region are believed to have prospered greatly from their production and trading of turquoise objects. The distinctive silver jewellery produced by the Navajo and other Southwestern Native American tribes today is a rather modern development, thought to date from around 1880 as a result of European influences. In Persia, turquoise was the de facto national stone for millennia, extensively used to decorate objects (from turbans to bridles), mosques, and other important buildings both inside and out, such as the Medresseh-i Shah Husein Mosque of Isfahan. The Persian style and use of turquoise was later brought to India following the establishment of the Mughal Empire there, its influence seen in high purity gold jewellery (together with ruby and diamond) and in such buildings as the Taj Mahal. Persian turquoise was often engraved with devotional words in Arabic script which was then inlaid with gold. Cabochons of imported turquoise, along with coral, was (and still is) used extensively in the silver and gold jewellery of Tibet and Mongolia, where a greener hue is said to be preferred.
Cardiac MRI is complementary to other imaging techniques, such as echocardiography, cardiac CT, and nuclear medicine. It can be used to assess the structure and the function of the heart. Its applications include assessment of myocardial ischemia and viability, cardiomyopathies, myocarditis, iron overload, vascular diseases, and congenital heart disease.
Sources: en.wikipedia.org
== Structure == Adiponectin is a 244-amino-acid-long polypeptide (protein). It has four distinct regions: The first is a short signal sequence that targets the hormone for secretion outside the cell; next is a short region that varies between species; the third is a 65-amino acid region with similarity to collagenous proteins; the last is a globular domain. Overall, this protein shows similarity to the complement 1Q factors (C1Q), but when the three-dimensional structure of the globular region was determined, a striking similarity to TNFα was observed, despite unrelated protein sequences.
The medication has largely been replaced by newer and improved NSAAs, namely bicalutamide and enzalutamide, due to their better efficacy, tolerability, safety, and dosing frequency (once per day), and is now relatively little-used. Flutamide is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
The three substrates of this enzyme are (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are (S)-2,3,4,5-tetrahydrodipicolinic acid], oxidised NAD+ and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is part of the biosynthesis pathway to lysine.
Be the single controlling body and administrator of the Game; Foster, develop, extend and provide adequate funding for the Game from the junior to elite levels and generally to act in the best interests of the Game; Liaise with and delegate appropriate functions to governing bodies of the Game in the States and Territories of Australia, including the NSWRL and QRL; Organise and conduct all State of Origin and Australian Representative Games; Organise, conduct and foster the NRL Competition; Liaise with the Rugby League International Federation Limited and organisations controlling the game in other countries in the fostering and control of the game of Rugby League throughout the world; Promote and encourage either directly or indirectly the physical, cultural and intellectual welfare of young people in the community and, in particular, the Rugby League community; Promote and encourage either directly or indirectly sport and recreation, particularly Rugby League football, in the interests of the social welfare of young persons.
== Phytochemicals == Buckwheat contains diverse phytochemicals, including rutin, tannins, catechin-7-O-glucoside in groats, and fagopyrins, mainly in the cotyledons of the buckwheat plant. It has almost no inorganic arsenic. Salicylaldehyde (2-hydroxybenzaldehyde) was identified as a characteristic component of buckwheat aroma. 2,5-dimethyl-4-hydroxy-3(2H)-furanone, (E,E)-2,4-decadienal, phenylacetaldehyde, 2-methoxy-4-vinylphenol, (E)-2-nonenal, decanal and hexanal also contribute to its aroma. They all have odour activity value of more than 50, but the aroma of these substances in an isolated state does not resemble buckwheat.
Sources: en.wikipedia.org
Prior to trans fat regulation, hydrogenation is generally not performed fully, resulting in partially hydrogenated fat. The goal is to have some unsaturated bonds (C=C bonds) to remain to target a specific melting point and hardness. However, due to the isomerization side reaction, a significant fraction of this remaining unsaturated fat is turned into trans fat. This side reaction accounts for most of the trans fatty acids consumed in an industrialized society of the 1990s-2000s, by far. Regulation has led to some desire in tweaking for lower trans fat levels. The standard 140 kPa (20 psi) process of partial hydrogenation produces a product of about 40% trans fatty acid by weight, compared to about 17% using higher pressures of hydrogen. Blended with unhydrogenated liquid soybean oil, the high-pressure-processed oil produced margarine containing 5 to 6% trans fat. Based on 2005 U.S. labeling requirements (see below), the manufacturer could claim the product was free of trans fat. The level of trans fat may also be altered by modification of the temperature and the length of time during hydrogenation. Further regulation and consumer awareness has led to wider adoption of fully hydrogenated fats, which contain no trans fat due to an absence of double bonds. The "overshoot" in melting point and hardness could be combated by mixing in another fat, sometimes using interesterification to produce a more even blend. Plant oils rich in monounsaturated fats and saturated fats have also replaced some uses of hydrogenated fats.
The genetic code was once believed to be universal: a codon would code for the same amino acid regardless of the organism or source. However, it is now agreed that the genetic code evolves, resulting in discrepancies in how a codon is translated depending on the genetic source. For example, in 1981, it was discovered that the use of codons AUA, UGA, AGA and AGG by the coding system in mammalian mitochondria differed from the universal code. Stop codons can also be affected: in ciliated protozoa, the universal stop codons UAA and UAG code for glutamine. Four novel alternative genetic codes (numbered here 34–37) were discovered in bacterial genomes by Shulgina and Eddy, revealing the first sense codon changes in bacteria. The following table displays these alternative codons.
As an international coalition under United States command assembled in anticipation of an invasion of Iraqi-occupied Kuwait, the Iraqi regime decided to destroy as much of Kuwait's oil reserves and infrastructure as possible before withdrawing from the country. As early as December 1990, Iraqi forces placed explosive charges on Kuwaiti oil wells. The wells were systematically sabotaged beginning on January 16, 1991, when the allies commenced air strikes against Iraqi targets. On February 8, satellite images detected the first smoke from burning oil wells. The number of oil fires peaked between February 22 and 24, when the allied ground offensive began. According to the U.S. Environmental Protection Agency's report to Congress, "the retreating Iraqi army set fire to or damaged over 700 oil wells, storage tanks, refineries, and facilities in Kuwait." Estimates placed the number of oil well fires from 605 to 732. A further thirty-four wells had been destroyed by heavy coalition bombing in January. The Kuwait Petroleum Company's estimate as of September 1991 was that there had been 610 fires, out of a total of 749 facilities damaged or on fire along with an unspecified number of oil filled low-lying areas, such as "oil lakes" and "fire trenches". These fires constituted approximately 50% of the total number of oil well fires in the history of the petroleum industry, and temporarily damaged or destroyed approximately 85% of the wells in every major Kuwaiti oil field. Concerted efforts to bring the fires and other damage under control began in April 1991.
==== Structure ==== The extracellular domains serve as the ligand-binding part of the molecule, often inducing the domains to form homo- or heterodimers. The transmembrane element is a single α helix. The intracellular or cytoplasmic Protein kinase domain is responsible for the (highly conserved) kinase activity, as well as several regulatory functions.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.